MODEL VERDICT
Zymeworks Inc. (ZYME)
Relative Valuation•Peer multiples, competitive benchmarking & quality-adjusted fair value
The market is pricing Zymeworks Inc. at a 11.16% premium to its peer-implied fair value.
13 industry peers matched by industry sector due to narrow curated coverage
| Ticker | Company | Market Cap | P/E | EV/EBITDA |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $114.88B | 29.48x | 22.88x |
| REGN | Regeneron Pharmaceuticals, Inc. | $63.37B | 14.7x | 15.28x |
| ARGX | argenx SE | $54.32B | 44.71x | 47.02x |
| ALNY | Alnylam Pharmaceuticals, Inc. | $37.1B | 119.35x | 65.91x |
| BNTX | BioNTech SE | $22.98B | -17.51x | - |
| UTHR | United Therapeutics Corporation | $22.78B | 19.26x | 13.24x |
| RPRX | Royalty Pharma plc | $22.69B | 29.42x | 19.84x |
| INCY | Incyte Corporation | $19.62B | 15.32x | 11.56x |
| GMAB | Genmab A/S | $15.51B | 16.41x | 14.54x |
| ASND | Ascendis Pharma A/S | $14.26B | -55.4x | - |
| JAZZ | Jazz Pharmaceuticals plc | $14.09B | -38.47x | 23.65x |
| EXEL | Exelixis, Inc. | $13.19B | 18.67x | 14.29x |
1 valuation metric · peer-median based
| Multiple | Current | Peer Median | vs Peers | Implied Price |
|---|---|---|---|---|
| Forward P/EPrice paid for next year's expected earnings. | 16.93x | 17.09x | Discount -0.95% | $23.36 |
How the model derives the final fair value from peer baselines and quality metrics
Premium: The stock is trading at a 12.57% premium to its quality-adjusted fair value of $20.56. The market is pricing the stock 11.16% above our model's estimate.
Quality metrics trail the peer group, warranting a discount.
Quality adjustments are capped at ±15% (up to ±20% for financial services) to prevent runaway premiums. Based on trailing twelve months and multi-year CAGR data where available.
Wall Street target prices — 20 analysts
Model-identified caveats to consider
ZYME has a limited relative valuation using L2 rescue peers after thin AI peer data; based mainly on Forward P/E, it looks slightly expensive versus peers.
Answers to common questions about ZYME's relative valuation and our methodology.
Zymeworks Inc.'s fair value of $20.56 is the price at which the stock would trade if valued at the same multiples as its 13-company peer group, adjusted for differences in business quality. At $23.14, the stock trades at a -11.15% premium to fair value. This is a reference point, not a price target.
Peers were grouped by industry classification and market capitalization. The 13 companies shown are the closest comparable names with clean, usable financial data.
Zymeworks Inc. has challenges in 3y revenue growth, roic, fcf margin, and a quality score that warrants a 12% discount relative to its peer group. The Quality Adjustment section breaks down each driver.
No. This page provides an automated quantitative comparison of Zymeworks Inc. against its peers. It is not investment advice, a recommendation, or a solicitation. Valuation is only one factor in an investment decision — it does not account for growth catalysts, management quality, regulatory risk, or your personal financial situation.
Look at the Historical Context to see where current multiples sit versus the stock's own history. Review the Risk Factors section for model-identified caveats. Compare the Analyst Consensus to our model output for another perspective. Valuation is only one dimension — growth trajectory, competitive position, and market conditions all matter.
Valuation data is refreshed weekly based on the latest financial filings, market prices, and analyst estimates. Zymeworks Inc.'s fair value, peer multiples, and quality scores will shift over time as new earnings are reported and stock prices change.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. Fair value estimates are model outputs under stated assumptions and should not be relied upon as the sole basis for any investment decision.